<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217488</url>
  </required_header>
  <id_info>
    <org_study_id>DG3173-I-001</org_study_id>
    <nct_id>NCT02217488</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Tolerability Study of DG3173</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspireo Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DeveloGen AG, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aspireo Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      This clinical trial investigated the safety, tolerability and pharmacokinetic profile of
      DG3173 in a double-blind, randomized, placebo-controlled, single dose escalation Phase 1
      study involving 72 healthy volunteers. Individuals received up to 2000 µg of DG3173 via
      single dose subcutaneous injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious adverse events or withdrawals due to adverse events</measure>
    <time_frame>One week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DG3173</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DG3173</intervention_name>
    <arm_group_label>DG3173</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ethnic origine: Caucasian

          -  Weight: 55-95 kg

          -  BMI: 19-29 kg/qm

          -  Medical history without clinically relevant pathologies

          -  Physical examination parameters and lung function without signs of clinically relevant
             pathologies

          -  Electrocardiogram recording without signs of clinically relevant pathology, in
             particular QTc (Bazett) &lt;440ms

          -  Values for hematology, biochemistry and for coagulation tests of blood and urine
             within the normal range or showing no clinically relevant deviation as judged by the
             medical investigator (in particular normal values for ALAT, ASAT, LDH, gamma-GT,
             alkaline phosphatase, alpha-amylase and bilirubin)

          -  Having given written informed consent before any study-related activities are carried
             out

        Exclusion Criteria:

          -  Evidence of clinically relevant pathology or disease

          -  Any history of moderate or severe hypertension, hypotension or orthostatic hypotension

          -  Mental handicap

          -  Legal incapacity

          -  Any history of clinically important emotional and/or psychiatric illness or of any
             clinically important neurological disorders and/or epilepsy

          -  Chronic diarrhea or other chronic gastrointestinal disorders

          -  Acute or chronic gastro-duodenal ulcers

          -  Presence or history of endocrine disorders

          -  Presence or history of gall stone disease, presence excluded by means of upper
             abdominal ultrasound

          -  Known hypersensitivity to the study drug or constituent of the study drug

          -  History of any relevant allergy, especially drug and/or food allergies

          -  Strict vegetarian

          -  Regular treatment with medications during three months prior to randomization

          -  Receipt of any prescription or non-prescription medication, including multi-vitamin
             preparations within 14 days prior to drug administration and for the duration of the
             study

          -  Use of St. John´s Wort or Ginkgo Biloba (also known as Ginkgo Bilbao) within 48 hours
             prior to randomization

          -  Participation in a clinical study within 30 days prior to randomization

          -  Donation of blood within 60 days prior to randomization

          -  History of use of tobacco or nicotine-containing products within the past three months

          -  Any history of alcohol abuse or drug addiction

          -  Positive results at screen for drugs of abuse (cocaine, amphetamine/methamphetamine,
             tetrahydrocannbinol, opiates) or alcohol (breath test) at screening or on admission

          -  Positive screen results for HBsAg, anti-HCV, or anti-HIV1&amp;2

          -  Consumption of abnormal quantities of coffee or tea (i.e. more than 5 cups per day [1
             cup = 150 ml]

          -  Any disease which in the Investigator´s opinion would exclude the subject from the
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2014</study_first_submitted>
  <study_first_submitted_qc>August 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

